Lung Disease Collection (Qatar): Evaluation of the Lungs of Individuals With Lung Disease (Q-LD)

This study has been completed.
Sponsor:
Collaborators:
Weill Cornell Medical College in Qatar
Hamad Medical Corporation
Information provided by (Responsible Party):
Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:
NCT00504738
First received: July 19, 2007
Last updated: December 22, 2011
Last verified: December 2011
  Purpose

The purpose of this protocol is to obtain biologic samples from the blood and lungs from patients with lung diseases in order to study the causes and indications of these disorders, learn how these lung disease manifest and progress, and how the lung disease can be treated.


Condition
Lung Disease
Chronic Obstructive Pulmonary Disease (COPD)
Asthma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Evaluation of the Lungs of Individuals With Lung Disease With Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing, and Bronchial Wall Biopsy (Qatar)

Resource links provided by NLM:


Further study details as provided by Weill Medical College of Cornell University:

Biospecimen Retention:   Samples With DNA

The purpose of this protocol is to obtain biologic samples from the blood and lungs from patients with lung diseases in order to study the causes and indications of these disorders, learn how these lung disease manifest and progress, and how the lung disease can be treated.


Enrollment: 75
Study Start Date: April 2006
Study Completion Date: April 2007
Detailed Description:

The lung diseases are disorders associated with functional and/or structural derangements to the alveolar structures, airways, pulmonary blood vessels, pleura and/or mediastinum. The purpose of this protocol is to obtain biologic materials from the blood and lungs from these patients in order to: (1) develop an understanding of the etiology and pathogenesis of these disorders; and (2) identify individuals who will be suitable candidates for other protocols such as those involving investigational new drugs. As such, this protocol is part of the "infrastructure" for all of our human lung-related studies such as genomic/gene expression studies of airway epithelium and alveolar macrophages in all individuals with chronic obstructive lung disease (COPD), asthma, bronchogenic carcinoma, and pulmonary fibrosis compared to normal non-smokers and smokers, and studies of mediators in bronchoalveolar lavage fluid.

This protocol, to be carried out at Weill Cornell Medical College - Qatar and Hamad Medical Corporation, Qatar, parallels a similar approved protocol IRB #0005004440, entitled, "Evaluation of the Lungs of Individuals with Lung Disease with Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing, and Bronchial Wall Biopsy", ongoing at Weill Cornell Medical College - New York.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Recruitment will be from the patients of the Hamad Medical Corporation and others as relevant. The source of potential subjects will be the population of potential subjects with lung disease, as defined by the elegibility criteria, in Qatar. Accrual will be random with no bias as to gender or racial/ethnic group.

Criteria

Inclusion Criteria:

Inclusion/Exclusion criteria for Part A

  • Must provide informed consent
  • Males and females, age 18 years and older
  • Evidence of lung disease by at least one of the following:

    1. symptoms consistent with pulmonary disease;
    2. chest X-rays and/or chest CT consistent with lung disease;
    3. pulmonary function tests consistent with lung disease;
    4. lung biopsy consistent with lung disease;
    5. family history of lung disease;
    6. diseases of organs with known association with lung disease; and
    7. individuals suspected of having lung disease based on history and/or physical examination
  • Undergoing fiberoptic bronchoscopy as dictated by their standard clinical care

Exclusion Criteria:

  • Patient refuses consent.

Patients enrolled in Part A of the protocol will not undergo screening procedures/tests. These patients are undergoing a fiberoptic bronchoscopy as dictated by their standard clinical care and additional samples will be taken for research purposes.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00504738

Locations
Qatar
Hamad Medical Corporation
Doha, Qatar
Sponsors and Collaborators
Weill Medical College of Cornell University
Weill Cornell Medical College in Qatar
Hamad Medical Corporation
Investigators
Principal Investigator: Ronald G. Crystal, MD Weill Cornell Medical College, New York and Qatar
  More Information

No publications provided

Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT00504738     History of Changes
Other Study ID Numbers: 0604008489, HMC RC392/2006
Study First Received: July 19, 2007
Last Updated: December 22, 2011
Health Authority: United States: Institutional Review Board
Qatar: Hamad Medical Corporation

Keywords provided by Weill Medical College of Cornell University:
lung disease
chronic obstructive pulmonary disease (COPD)
asthma
smokers
non-smokers

Additional relevant MeSH terms:
Asthma
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Bronchial Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on July 26, 2014